Influence of dietary amiloride supplement on the zinc status of growing rats with marginal zinc supply.

We divided 36 male pathogen-free Sprague-Dawley rats with an average live mass (LM) of 51 g into four treatment groups of nine animals each. They received for a period of 28 trial days a semisynthetic purified diet based on casein for ad libitum consumption, supplemented with 5 ppm zinc (groups 1-3) or 57 ppm zinc (group 4) as zinc sulfate. In addition to the diet, groups 2 and 3 were given a diuretic supplement of amiloride at the therapeutic dose rate (0.4 mg amiloride/kg LM0.75 per day) or in a dosage corresponding to the chronic toxicity level (maximum tolerated dose; 0.8 mg amiloride/kg LM0.75 per day). The supplementation with amiloride, acting as a potential Zn-binding ligand at the selected dosage levels, had no influence on the animals' live weight during the 28-day trial period; weight gain was determined solely by the dietary Zn concentration. Amiloride administered at the therapeutic or the maximum tolerated dose produced no evidence of a diminished Zn status in terms of the alkaline phosphatase activity in the serum or the Zn concentration in the serum, femur and testes. Medication with amiloride at the maximum tolerated dose even exerted a positive effect on the zinc supply status as demonstrated by the raised Zn concentration in the serum. This suggests that zinc supplementation may not be required during medication with amiloride in human medicine.